Frontotemporal dementia and parkinsonism (FTDP) is
INTRODUCTION
Recently, several families have been reported in which an insidious presenile form of dementia with prominent behavioural disturbance and motor manifestations segregates as an autosomal dominant trait. In some families, the pathological locus was mapped to a 2 cM interval on 17q21-22 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) and the corresponding condition was therefore designated frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) (12) . However, genetic heterogeneity has been demonstrated, since another locus for frontotemporal dementia has been mapped on chromosome 3 in a single large pedigree (13) .
Despite descriptions that have emphasized one or another clinical or neuropathological feature, FTDP-17 kindreds share similar characteristics: gross neuropathological examination shows atrophy of the frontotemporal and basal ganglia contrasting with relative sparing of the hippocampus. In some, but not all, cases, microscopical examination of affected brains reveals tau-positive neuronal inclusions, without the characteristics of Pick bodies, and/or tau-positive glial inclusions (12) . The gene coding for the human microtubule-associated protein tau (MAPT) is located on 17q21 and is therefore a strong candidate for FTDP-17. However, in three FTDP-17 families, analysis of the MAPT coding sequence had failed to detect any pathogenic mutation in affected subjects (4, 8, 9) . We had previously identified 21 French pedigrees with FTDP and we report in this study identification of the same MAPT mutation in six families.
RESULTS
We studied 21 families with FTDP, in which age of onset ranged from 38 to 73 years (Table 1) . For each family, we analysed the MAPT gene in one affected proband. Direct sequencing of the MAPT exons revealed in six families the same C→T substitution (CCG→CTG) in exon 10 (data not shown), resulting in a Pro→Leu change at amino acid 301 (Table 1) . This substitution removes an MspI restriction site which allowed simple confirmation of the mutation in index cases and detection of the mutation in the relatives. Co-segregation of the Pro301Leu mutation with the disease was established in two families for which DNA from several relatives was available (Fig. 1) . In other pedigrees, lack of living affected relatives precluded such an analysis. The Pro301Leu mutation was not observed in 50 unrelated controls and in 11 patients with *To whom correspondence should be addressed. T. sporadic frontotemporal dementia from the French population. In addition, six other MAPT nucleotide variations were also identified in affected probands of the FTDP families (Table 2) .
DISCUSSION
We have detected a missense mutation (Pro301Leu) of the MAPT gene in six French FTDP families. The human MAPT gene includes 11 coding exons (1-5, 7 and 9-13). In human brain, exons 2, 3 and 10 are alternatively spliced, thus producing six different isoforms, which range from 352 to 441 amino acids and differ from each other by the presence or absence of three inserts (14) . Although we cannot exclude that the Pro301Leu substitution is in linkage disequilibrium with the causal mutation, this mutation, located in exon 10, is likely to be pathogenic. (i) This substitution, which is predicted to produce a drastic change in the conformation of the protein, occurs in the second of four repeats (Pro-Gly-Gly-Gly) located in the C-terminal half of the MAPT protein which are highly conserved among species. These repeats constitute the microtubule-binding domains, which suggests that the Pro301Leu mutation might alter binding to the microtubule. However, since exon 10 is alternatively spliced in human brain, this mutation will only affect the subset of MAPT isoforms containing the four microtubule-binding domains. (ii) The Pro301Leu was not found in 50 French controls, indicating that this variation is not a common polymorphism. (iii) Co-segregation analysis, performed in two families (Fig. 1) confirmed that the Pro301Leu mutation is probably involved in FTDP. In contrast, the six other MAPT sequence variations that we have detected correspond to polymorphisms, since they were observed in unaffected controls (Table 2) . Furthermore, five out of these six variations were observed in the proband of family ROU 100 harbouring the Pro301Leu mutation, were homozygous in some probands (Tables 1 and 2 ) and the three variations identified in exons 7 and 9 do not change the amino acid.
In the six families in which we identified the Pro301Leu mutation, the age of onset ranged from 46 to 62 years ( Table 1 ), suggesting that other genetic or non-genetic factors may interact with MAPT mutations to determine onset of the disease. In families with early-onset Alzheimer's disease associated with APP mutations, such an interaction has been documented with the ApoE genotype and it has been reported that the ApoE4 isoform decreases the age of onset (15) , possibly via an interaction between MAPT and ApoE (16) . It has also been reported that in sporadic frontal lobe dementia, the age of onset decreases as the number of APOE ε4 allele increases (17) . In this study, the 10 affected individuals harbouring the Pro301Leu mutation and corresponding to six distinct families (Table 1) had an ApoE ε3/ε3 genotype. This result is not surprising, since the ε3 allele frequency in the French population is ∼0.8. Considering the variation in age of onset observed in these families (Table 1) , this result does not support the hypothesis that APOE is a modifier gene in FTDP-17 families.
While this study was in progress, three groups have reported the occurrence of various MAPT mutations in FTDP-17 (18) (19) (20) . The Pro301Leu mutation was also identified in two families originating from The Netherlands and from the USA (19) . Strikingly, we detected this mutation in six out of 21 families of French origin. This high proportion might suggest that, in the French population, the Pro301Leu mutation could result from a founder effect. (Fig. 1) . c Detected in two affected individuals (Fig. 1) . d No pathogenic mutation was detected. In 15 FTDP families, we did not detect any pathogenic mutation in the MAPT coding region. Since we had no linkage data for these families, we cannot exclude that these negative results might be explained by genetic heterogeneity. The alternative hypothesis is that, at least in some families, MAPT mutations might fall outside the coding region, such as in the promoter or the introns.
From a biological point of view, identification of the Pro301Leu mutation in eight FTDP families (this study; 19) may be highly informative. Since this mutation is located in one of the microtubule-binding domains of the MAPT protein, it could be speculated that disruption of binding of the MAPT protein to the microtubule is a key event in the pathogenesis of FTDP.
MATERIALS AND METHODS

Patients
Twenty one FTDP families with autosomal dominant inheritance were selected for this study. All affected subjects fulfilled the Lund and Manchester criteria for frontotemporal dementia (21): they presented with similar clinical features, including behaviou-ral disturbances (disinhibition, stereotypic behaviour and apathy), memory impairment, relative preservation of spatial orientation and speech disturbance with reduced speech output progressing to muteness. CT scans showed frontotemporal atrophy and functional imaging anterior hypoperfusion. As shown in Table 1 , ages of onset were mainly in the fifth or sixth decade. Eleven patients with sporadic frontotemporal dementia were selected using the same clinical criteria. After informed consent was obtained, peripheral blood lymphocytes were collected and genomic DNA was extracted using a standard procedure. 
Sequencing analysis
Exons 1-5, 7 and 9-14 of the MAPT gene and the corresponding flanking intronic sequences were PCR amplified using the primers described by Froelich et al. (9) and primers described in Table 3 . PCR reactions were performed in a final volume of 50 µl containing 0.5 µM each primer and 1 U Taq DNA polymerase (Eurobio). The PCR consisted of 40 cycles of 15 s at 94_C, 15 s at 50-60_C and 40 s at 72_C, preceded by 2 min at 95_C and followed by 5 min at 72_C. PCR products were purified by electrophoresis on low melting point agarose gels and directly sequenced on both strands using the PRISM AmpliTaqFS Ready Reaction Dye Terminators or Rhodamine Dye Terminators sequencing kits (Applied Biosystems, Perkin Elmer-Cetus) and an Applied Biosystems model 373A or 377 automated sequencer. Nucleotide sequences obtained in patients were compared with that obtained in a neurologically normal subject using the SeqEd 675 DNA Sequence Editor Software (Applied Biosystems, Perkin Elmer-Cetus).
Restriction fragment analysis
Screening for the Pro301Leu mutation was performed on genomic DNA by restriction fragment analysis. A 271 bp fragment was amplified with the 10F and 10R primers (Table 3) and one third of the PCR reaction (15 µl) was digested with 15 U MspI restriction enzyme (New England Biolabs) for 2 h in a final volume of 20 µl and resolved on a 3% agarose gel. ApoE genotypes were determined according to Hixson and Vernier (22) .
